DR. MICHAEL B CHANCELLOR, MD
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD041546L
Category
Medical Practice
Type
Specialist
Address
Address
3471 Ave Lkb SUITE 700, Pittsburgh, PA 15213
Phone
(412) 692-4100
Personal information
See more information about MICHAEL B CHANCELLOR at radaris.comName
Address
Phone
5836 Ferree St, Pittsburgh, PA 15217
Professional information
Professor Of Urology
Position:
Professor at Oakland University William Beaumont School of Medicine, CSO at Lipella Pharmaceuticals Inc.
Location:
Pittsburgh, Pennsylvania
Industry:
Biotechnology
Work:
Oakland University William Beaumont School of Medicine
- Royal Oak and Pittsburgh since 2008
-
Professor
Lipella Pharmaceuticals Inc.
since 2008
-
CSO
Education:
University of Michigan 1976 - 1979
Muscle Derived Cells For The Treatment Of Urinary Tract Pathologies And Methods Of Making And Using The Same
US Patent:
2012010, May 3, 2012
Filed:
Dec 23, 2011
Appl. No.:
13/336332
Inventors:
Michael B. Chancellor - Pittsburgh PA, US
Ronald Jankowski - Pittsburgh PA, US
Ryan Pruchnic - Pittsburgh PA, US
Johnny Huard - Wexford PA, US
Ronald Jankowski - Pittsburgh PA, US
Ryan Pruchnic - Pittsburgh PA, US
Johnny Huard - Wexford PA, US
Assignee:
University of Pittsburg-Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61M 37/00, A61P 13/02, C12N 5/071, A61K 35/34
US Classification:
604522, 424 937, 435366, 435325, 435353, 435350
Abstract:
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for urinary incontinence and other urinary tract pathologies.
Rapid Preparation Of Stem Cell Matrices For Use In Tissue And Organ Treatment And Repair
US Patent:
2011022, Sep 15, 2011
Filed:
Mar 11, 2011
Appl. No.:
13/046120
Inventors:
Michael B. Chancellor - Pittsburgh PA, US
Johnny Huard - Wexford PA, US
Christopher Capelli - Kenosha WI, US
Steve Chung - Pittsburgh PA, US
Michael S. Sacks - Pittsburgh PA, US
Johnny Huard - Wexford PA, US
Christopher Capelli - Kenosha WI, US
Steve Chung - Pittsburgh PA, US
Michael S. Sacks - Pittsburgh PA, US
International Classification:
A61K 35/34, A61P 17/02
US Classification:
424 937
Abstract:
A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition.
Muscle Derived Cells For The Treatment Of Gastro-Esophageal Pathologies And Methods Of Making And Using The Same
US Patent:
2010015, Jun 24, 2010
Filed:
Aug 25, 2009
Appl. No.:
12/547149
Inventors:
Michael B. Chancellor - Pittsburgh PA, US
Jay Pasricha - Cupertino CA, US
Ronald Jankowski - Pittsburgh PA, US
Ryan Pruchnic - Pittsburgh PA, US
Jay Pasricha - Cupertino CA, US
Ronald Jankowski - Pittsburgh PA, US
Ryan Pruchnic - Pittsburgh PA, US
Assignee:
University of Pittsburgh - of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 35/12, A61P 1/04
US Classification:
424 937
Abstract:
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux.
Muscle Derived Cells For The Treatment Of Cardiac Pathologies And Methods Of Making And Using The Same
US Patent:
8211423, Jul 3, 2012
Filed:
Nov 28, 2007
Appl. No.:
11/998330
Inventors:
Michael B. Chancellor - Pittsburgh PA, US
Thomas Payne - Pittsburgh PA, US
Ronald Jankowski - Pittsburgh PA, US
Ryan Pruchnic - Pittsburgh PA, US
Thomas Payne - Pittsburgh PA, US
Ronald Jankowski - Pittsburgh PA, US
Ryan Pruchnic - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
A01N 63/00, C12N 5/07
US Classification:
424 937, 435325, 435366
Abstract:
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e. g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
Soft Tissue And Bone Augmentation And Bulking Utilizing Muscle-Derived Progenitor Cells, Compositions And Treatments Thereof
US Patent:
8580561, Nov 12, 2013
Filed:
Apr 12, 2006
Appl. No.:
11/403788
Inventors:
Michael B. Chancellor - Pittsburgh PA, US
Johnny Huard - Wexford PA, US
Christopher C. Capelli - Kenosha WI, US
Zhuqing Qu - Pittsburgh PA, US
Johnny Huard - Wexford PA, US
Christopher C. Capelli - Kenosha WI, US
Zhuqing Qu - Pittsburgh PA, US
Assignee:
University of Pittsburgh—Of The Commonwealth System Of Higher Education - Pittsburgh PA
International Classification:
C12N 5/00, C12N 5/071
US Classification:
435325, 435363, 435366
Abstract:
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e. g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
Application Of Lipid Vehicles And Use For Drug Delivery
US Patent:
2007000, Jan 4, 2007
Filed:
May 22, 2006
Appl. No.:
11/438912
Inventors:
Michael Chancellor - Pittsburgh PA, US
Matthew Fraser - Apex NC, US
Yao-Chi Chuang - Kaohsiung Hsein, TW
William de Groat - Pittsburgh PA, US
Leaf Huang - Pittsburgh PA, US
Naoki Yoshimura - Pittsburgh PA, US
Matthew Fraser - Apex NC, US
Yao-Chi Chuang - Kaohsiung Hsein, TW
William de Groat - Pittsburgh PA, US
Leaf Huang - Pittsburgh PA, US
Naoki Yoshimura - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
A61K 39/08, A61K 9/127, A61K 31/16, A61K 48/00
US Classification:
424450000, 424239100, 514044000, 424133100, 514630000
Abstract:
The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.
Soft Tissue And Bone Augmentation And Bulking Utilizing Muscle-Derived Progenitor Cells, Compositions And Treatments Thereof
US Patent:
2007006, Mar 22, 2007
Filed:
Aug 17, 2006
Appl. No.:
11/505734
Inventors:
Michael Chancellor - Pittsburgh PA, US
Johnny Huard - Pittsburgh PA, US
Christopher Capelli - Kenosha WI, US
Zhuqing Qu - Pittsburgh PA, US
Johnny Huard - Pittsburgh PA, US
Christopher Capelli - Kenosha WI, US
Zhuqing Qu - Pittsburgh PA, US
International Classification:
A61K 35/12, C12N 5/08
US Classification:
424093700, 435325000, 435366000
Abstract:
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
Instillation Of Liposomal Formulation Of Sirna And Antisense Oligonucleotides
US Patent:
2011027, Nov 10, 2011
Filed:
Nov 10, 2010
Appl. No.:
12/943652
Inventors:
Michael B. Chancellor - Pittsburgh PA, US
Jonathan Howard Kaufman - Pittsburgh PA, US
Jonathan Howard Kaufman - Pittsburgh PA, US
International Classification:
A61K 9/127, A61P 13/10, A61P 13/02, A61K 31/7088
US Classification:
424450, 514 44 A
Abstract:
A pharmaceutically acceptable deliverable composition and methods for administration of macromolecules for sequence-specific gene-silencing in bladder to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS), lower urinary tract symptoms (LUTS) locally in the bladder, or other diseases or disorders of the bladder or LUTS, has been discovered. In the preferred embodiment, a liposome based delivery system is used to deliver an effective amount of antisense oligonucleotides (ODN) or siRNA that interact with or bind to messenger RNA (mRNA) coding for human nerve growth factor (NGF) to stop the synthesis of NGF.
Methods And Systems For Achieving A Physiological Response By Pudendal Nerve Stimulation And Blockade
US Patent:
2009003, Feb 5, 2009
Filed:
Aug 1, 2008
Appl. No.:
12/184518
Inventors:
Michael B. Chancellor - Pittsburgh PA, US
Changfeng Tai - Wexford PA, US
Changfeng Tai - Wexford PA, US
International Classification:
A61N 1/36
US Classification:
607 39, 607 41
Abstract:
Methods and apparatus are therefore provided herein for stimulating a desired physiological effect. The methods and apparatus can be used to control micturition, defecation and/or ejaculation. The methods and apparatus also can be used to control pain in the lower pelvic region, for example and without limitation, interstitial cystitis. The methods and apparatus also can be used to increase sexual sensation.